ChemotherapyFDA-approvedFirst-line
Paclitaxel
How it works
Interferes with cell division, preventing cancer cells from growing and dividing.
Cancer types
Efficacy
Studies show that paclitaxel can improve survival and response rates in ovarian cancer patients, with a median overall survival of approximately 22 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Combination Therapy Shows Promise for Small-Cell Lung Cancer | Lung Cancer | phase-2 | The median progression-free survival was 6.0 months in the ANNAB group and 4.7 months in the NAP group (p = 0.0004). | Source → |
| Ovarian Cancer Treatment Trial Evaluates IMNN-001 Combination Therapy | Ovarian Cancer | phase-1 | — | Source → |
| Testing B013 with Paclitaxel for Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Immunotherapy with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| CTDSPL2 linked to paclitaxel resistance in breast cancer cells | Breast Cancer | lab-study | — | Source → |
| Testing DT2216 and Paclitaxel in Platinum-Resistant Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Testing Combination Therapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing a Combination Treatment for Unresectable Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combination Therapy for Resectable Pancreatic Cancer Before Surgery | Pancreatic Cancer | phase-2 | — | Source → |
| Chemotherapy's Effect on Gut Microbiome in Breast Cancer Patients | Breast Cancer | animal-study | — | Source → |
| Targeted Paclitaxel Delivery for Breast Cancer | Breast Cancer | review | — | Source → |
| Herbal Formula Enhances Chemotherapy Effectiveness in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Testing Fostamatinib with Chemotherapy in Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Testing a New Combination of Medications for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Oregovomab with Chemo and Bevacizumab in Ovarian Cancer | Ovarian Cancer | phase-1 | — | Source → |
| Researchers Identify Lipid Biomarkers for Paclitaxel Side Effect | Breast Cancer | observational | — | Source → |
| New Oral Paclitaxel Shows Similar Efficacy to IV Paclitaxel in Breast Cancer | Breast Cancer | phase-2 | The objective response rate was 25.0% with DHP107 and 28.6% with IV paclitaxel. | Source → |
| Testing Oral Paclitaxel as First-Line Treatment for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Study of Genetic Causes of Neuropathy in Breast Cancer Patients | Breast Cancer | preclinical | — | Source → |
| Testing a New Treatment for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| First-line Treatment Study for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-3 | — | Source → |
| Testing IACS-6274 with or without Bevacizumab and Paclitaxel for Advanced Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Testing CFI-402257 with Paclitaxel in Advanced Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Ovarian Cancer Treatment Trial: Pembrolizumab and Paclitaxel Combination | Ovarian Cancer | phase-3 | — | Source → |
| Testing a Combination Treatment for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Paclitaxel Infusion Study | Breast Cancer | preclinical | — | Source → |
| Paclitaxel for Breast Cancer: A Bioequivalence Study | Breast Cancer | preclinical | — | Source → |
| Paclitaxel Linked to Rare Heart Condition in Breast Cancer Patient | Breast Cancer | observational | — | Source → |
| Link between erythropoietin receptor and ovarian cancer resistance found | Breast Cancer | lab-study | — | Source → |
| Delivering Cancer Medicine with Stem Cell Exosomes | Pancreatic Cancer | lab-study | PTX-loaded exosomes significantly enhanced cytotoxicity compared to free PTX, reducing IC values from 12.48 nM to 7.55 nM in BxPC-3 cells and from 22.44 nM to 19.29 nM in PANC-1 cells. | Source → |
| Vitamin B May Help Reduce Side Effects of Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | A significant reduction in CIPN grade over time was found, with fewer patients progressing to higher grades in the prophylactic versus non-prophylactic group. | Source → |
| ZNF184 Linked to Breast Cancer Resistance to Paclitaxel | Breast Cancer | lab-study | — | Source → |
| TMEPAI Protein Contributes to Paclitaxel Resistance in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Nanosystem Combines Two Cancer Treatments for Better Effect | Melanoma | lab-study | — | Source → |
| Combining Camrelizumab with Gemcitabine and Paclitaxel in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | The median overall survival was 14.0 months, and the median progression-free survival was 6.4 months. | Source → |
| Nanoformulated Phytochemicals Show Promise Against Pancreatic Cancer | Pancreatic Cancer | preclinical | — | Source → |
| Paclitaxel treatment may enhance immune response in aggressive breast cancer | Breast Cancer | lab-study | — | Source → |
| Linoleic Acid May Reduce Effectiveness of Paclitaxel in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Comparing Two Cancer Treatments for Ovarian Cancer | Ovarian Cancer | observational | The frequency of peripheral neuropathy in the nab-paclitaxel cohort (14%) was half that of the paclitaxel cohort (28%). | Source → |
| Paclitaxel Resistance in Ovarian Cancer: A Potential Target for Treatment | Ovarian Cancer | lab-study | — | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer | Ovarian Cancer | phase-2 | A 1-month improvement in median progression-free survival and overall survival improvement was seen in the combination arm versus single-agent nab-paclitaxel. | Source → |
| Combining paclitaxel and anlotinib for ovarian cancer treatment | Ovarian Cancer | phase-2 | The investigator-evaluated objective response rate was 56.8% in the intention-to-treat population. | Source → |
| Paclitaxel-resistant cancer cells may rely on unstable microtubules | Breast Cancer | lab-study | — | Source → |
| Comparing Treatments for Early Recurring Pancreatic Cancer | Pancreatic Cancer | observational | The gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group. | Source → |
| Paclitaxel Nanoemulsions Show Promise in Treating Breast Cancer | Breast Cancer | lab-study | The nanoemulsion amplified paclitaxel-mediated chromatin condensation and expression of proteins involved in apoptosis, with a 2.5-fold increase in PARP1 cleavage and a 1.7-fold downregulation of BCL2 expression. | Source → |
| Hydrogen Sulfide May Enhance Paclitaxel's Effectiveness Against Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Researchers Identify Potential Target for Paclitaxel-Resistant Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Ovarian Cancer Cells Show Resistance to Paclitaxel in Lab Experiments | Ovarian Cancer | lab-study | — | Source → |
| Combining Paclitaxel with Autophagy Inhibitor May Improve Breast Cancer Treatment | Breast Cancer | animal-study | — | Source → |
| Combining Radiation and Chemotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-1 | The median overall survival was 22.3 months. | Source → |
| Vitamin E Form δ-Tocotrienol May Enhance Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Understanding Paclitaxel's Effect on Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Gemcitabine and Nab-paclitaxel Combination Therapy Linked to Lung Disease in Pancreatic Cancer Patients | Pancreatic Cancer | meta-analysis | — | Source → |
| New Injectable Gel for Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Tenacissoside G May Help Overcome Paclitaxel Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Rare Side Effect of Cancer Treatment Affects Vision | Pancreatic Cancer | observational | — | Source → |
| Real-world Outcomes for Pancreatic Cancer Treatment | Pancreatic Cancer | review | In 9/17 clinical studies, median overall survival (mOS) ranged from 4.7 months to 11.4 months for FFX/mFFX, with the unweighted median of the estimates within this range being 9.2 months. | Source → |
| Combining Nadunolimab with Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer | Pancreatic Cancer | phase-2 | The median overall survival was 13.2 months, and the 1-year survival rate was 58%. | Source → |
| Hereditary Breast-Ovarian Cancer Syndrome Responds to Chemotherapy | Ovarian Cancer | observational | The patient exhibited an outstanding response to the chemotherapy agents, Carboplatin and Paclitaxel. | Source → |
| Comparing Chemotherapy Options for Advanced Pancreatic Cancer | Pancreatic Cancer | meta-analysis | — | Source → |
| New Study Compares Treatments for Rare Ovarian Tumors | Ovarian Cancer | phase-2 | Median progression-free survival was 27.7 months for paclitaxel and carboplatin, and 19.7 months for bleomycin, etoposide, and cisplatin. | Source → |
| Factors Affecting Chemotherapy-Induced Peripheral Neuropathy in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | — | Source → |
| New Paclitaxel Conjugate Shows Promise in Cancer Treatment | Lung Cancer | lab-study | PTX-RPPR inhibited tumor cell proliferation with an IC ranging from 0.26 to 1.64 μM. | Source → |
| Combining Paclitaxel and Cediranib for Ovarian Cancer Patients at Risk of Bowel Obstruction | Ovarian Cancer | phase-2 | The objective response in patients who received paclitaxel and cediranib was 65.0%. | Source → |
| Paclitaxel Sensitivity in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Nanoparticle Delivery System for Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| New Approach to Overcome Paclitaxel Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Researchers Use Human Fat Cells to Deliver Cancer Drug | Ovarian Cancer | lab-study | The study induced a significant inhibition of tumor growth on a xenograft tumor model. | Source → |
| Paclitaxel Resistance in Breast Cancer Cells | Breast Cancer | lab-study | — | Source → |
| Combining two treatments may slow pancreatic cancer growth | Pancreatic Cancer | animal-study | Sel-GemPac enhanced the survival of treated mice compared to controls (p < .05). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.